Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with high-risk alcohol consumption were equally likely to achieve a cure with direct-acting antivirals.
Nearly all study participants were cured after re-treatment following liver transplantation.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
Initiating HCV treatment during a hospital stay helped more people complete antiviral treatment and achieve a cure.
Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.
Offering hepatitis C treatment at the point of diagnosis streamlines care, saving both time and money.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
Egypt has diagnosed 87% of people living with hepatitis C and provided curative treatment for 93% of those diagnosed.
Hepatitis C prevalence was higher among people with unstable housing and those who injected drugs every day.
Only 20% of people covered by Medicaid received treatment within six months of their HCV diagnosis.
Modern antivirals can cure 95% of people with HCV, lowering the risk of cirrhosis, liver cancer and liver failure.
Adding ribavirin led to more side effects but did not improve the likelihood of a cure.
Older people, men and people living in poverty and lacking private insurance were more likely to have active HCV infection.
The CDC estimates that 21% of people living with HIV also have hepatitis C virus.
Drug-related mortality, including overdose, was the leading cause of death.
Researchers are working on a cure for hepatitis B and a vaccine and long-acting antivirals for hepatitis C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.